167.41
前日終値:
$168.73
開ける:
$166.76
24時間の取引高:
941.43K
Relative Volume:
0.85
時価総額:
$18.72B
収益:
$9.54B
当期純損益:
$841.00M
株価収益率:
22.50
EPS:
7.44
ネットキャッシュフロー:
$1.02B
1週間 パフォーマンス:
-2.61%
1か月 パフォーマンス:
-6.80%
6か月 パフォーマンス:
+2.64%
1年 パフォーマンス:
+17.65%
Quest Diagnostics Inc Stock (DGX) Company Profile
DGX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
DGX
Quest Diagnostics Inc
|
167.41 | 18.87B | 9.54B | 841.00M | 1.02B | 7.44 |
![]()
TMO
Thermo Fisher Scientific Inc
|
467.68 | 180.17B | 43.21B | 6.58B | 6.17B | 17.29 |
![]()
DHR
Danaher Corp
|
197.16 | 146.07B | 24.01B | 3.41B | 4.86B | 4.70 |
![]()
IDXX
Idexx Laboratories Inc
|
534.31 | 46.01B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
A
Agilent Technologies Inc
|
114.81 | 33.53B | 6.63B | 1.17B | 1.19B | 4.05 |
![]()
IQV
Iqvia Holdings Inc
|
185.86 | 32.56B | 15.50B | 1.33B | 2.16B | 7.34 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-02 | 開始されました | Redburn Atlantic | Buy |
2025-03-04 | ダウングレード | Citigroup | Buy → Neutral |
2025-01-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
2024-12-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2024-12-10 | 再開されました | Jefferies | Buy |
2024-10-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
2024-08-28 | 再開されました | Evercore ISI | In-line |
2024-07-10 | アップグレード | Citigroup | Neutral → Buy |
2024-02-26 | 開始されました | Leerink Partners | Market Perform |
2024-02-07 | アップグレード | Jefferies | Hold → Buy |
2024-01-03 | 開始されました | Barclays | Equal Weight |
2023-12-12 | アップグレード | BofA Securities | Neutral → Buy |
2023-06-29 | 開始されました | Piper Sandler | Neutral |
2023-05-02 | ダウングレード | BofA Securities | Buy → Neutral |
2023-04-03 | アップグレード | Citigroup | Sell → Neutral |
2023-01-23 | 開始されました | Evercore ISI | In-line |
2022-11-17 | ダウングレード | Citigroup | Neutral → Sell |
2022-08-22 | 再開されました | Morgan Stanley | Equal-Weight |
2022-04-04 | ダウングレード | Citigroup | Buy → Neutral |
2022-02-23 | ダウングレード | UBS | Buy → Neutral |
2022-02-02 | ダウングレード | Jefferies | Buy → Hold |
2022-01-28 | ダウングレード | Deutsche Bank | Buy → Hold |
2021-05-04 | アップグレード | UBS | Neutral → Buy |
2021-03-12 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2020-10-21 | アップグレード | Argus | Hold → Buy |
2020-07-29 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
2020-07-14 | アップグレード | BofA Securities | Neutral → Buy |
2020-06-09 | アップグレード | Wells Fargo | Underweight → Equal Weight |
2020-06-02 | アップグレード | Deutsche Bank | Hold → Buy |
2020-04-28 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2020-04-27 | アップグレード | Citigroup | Neutral → Buy |
2020-04-27 | アップグレード | Wolfe Research | Underperform → Peer Perform |
2020-03-27 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2020-01-08 | 開始されました | Wells Fargo | Underweight |
2020-01-07 | ダウングレード | Barclays | Overweight → Equal Weight |
2019-12-19 | アップグレード | BofA/Merrill | Underperform → Neutral |
2019-07-15 | ダウングレード | Goldman | Neutral → Sell |
2019-04-02 | アップグレード | Jefferies | Hold → Buy |
2019-03-18 | 再開されました | Credit Suisse | Neutral |
2019-01-31 | ダウングレード | Argus | Buy → Hold |
2019-01-17 | 開始されました | UBS | Neutral |
2019-01-03 | ダウングレード | BofA/Merrill | Neutral → Underperform |
2018-12-03 | ダウングレード | BofA/Merrill | Buy → Neutral |
2018-11-30 | ダウングレード | Goldman | Buy → Neutral |
すべてを表示
Quest Diagnostics Inc (DGX) 最新ニュース
Drug Abuse Testing Market Forecast and Company Analysis - GlobeNewswire
Drug Abuse Testing Market Forecast and Company Analysis Report 2025-2033 Featuring Danaher, LabCorp, Abbott, Quest Diagnostics, Thermo Fisher Scientific, F. Hoffmann-La Roche, Bio-Rad, Medtronic - Yahoo Finance
Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing - Financial Times
North America Autoimmune Disease Diagnostics Market Report - GlobeNewswire
North America Autoimmune Disease Diagnostics Market Report 2025-2033 Featuring Bio-Rad, Abbott, Roche, Quest Diagnostics, Thermo Fisher Scientific, BioMerieux, Myriad Genetics, Siemens Healthineers - Yahoo Finance
What makes Quest Diagnostics Incorporated stock price move sharplyTrade Setups With Clear Risk Limits Highlighted - metal.it
Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term - sharewise.com
What is the risk reward ratio of investing in Quest Diagnostics Incorporated stockInvest smarter with real-time trading alerts - jammulinksnews.com
Why is Quest Diagnostics Incorporated stock attracting strong analyst attentionTremendous portfolio expansion - jammulinksnews.com
Published on: 2025-07-28 06:28:08 - jammulinksnews.com
What are the technical indicators suggesting about Quest Diagnostics IncorporatedUnlock powerful stock screening techniques - jammulinksnews.com
What catalysts could drive Quest Diagnostics Incorporated stock higher in 2025Sky-high profits - jammulinksnews.com
Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Quest Diagnostics (NYSE:DGX) Stock Price - MarketBeat
Quest Diagnostics Incorporated Stock Analysis and ForecastPhenomenal capital gains - PrintWeekIndia
What analysts say about Quest Diagnostics Incorporated stockDynamic growth stocks - PrintWeekIndia
How high can Quest Diagnostics Incorporated stock price go in 2025High-performance investment picks - jammulinksnews.com
Quest Diagnostics Trading Volume Drops 31.43% to $364 Million Ranking 317th Despite Stock Price Rise - AInvest
Options Corner: Quest Diagnostics' Post-Earnings Digestion Drama Opens A Science-Backed Opportunity - inkl
Quest Diagnostics’ revenue up 15.2% to USD 2.76B in Q2 2025 - Medical Buyer
Barclays Reaffirms Their Hold Rating on Quest Diagnostics (DGX) - The Globe and Mail
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight - GuruFocus
Quest Diagnostics Incorporated's (NYSE:DGX) Shares May Have Run Too Fast Too Soon - 富途牛牛
Quest Diagnostics (DGX) Price Target Raised by UBS, Rating Maint - GuruFocus
U.S. DTC Wellness Testing Market Forecast to 2030: A $1.91 - GlobeNewswire
Quest Diagnostics (DGX) Price Target Raised by Deutsche Bank Ana - GuruFocus
Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 - ADVFN Brasil
Quest Diagnostics Incorporated (NYSE:DGX) Q2 2025 Earnings Call Transcript - Insider Monkey
Quest Diagnostics (DGX) Price Target Raised by Deutsche Bank | D - GuruFocus
Is Quest Diagnostics Incorporated a good long term investmentConsistently exceptional gains - Autocar Professional
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MSN
Quest Diagnostics Inc (DGX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised ... - Yahoo Finance
Quest Diagnostics Inc (DGX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised ... By GuruFocus - Investing.com Canada
DGX Q2 Deep Dive: Acquisitions, Advanced Diagnostics, and Utilization Trends Drive Growth - TradingView
What drives Quest Diagnostics Incorporated stock priceBreakthrough financial growth - jammulinksnews.com
Quest Diagnostics Lifts Outlook As Testing Demand Grows - Finimize
Quest Diagnostics Surges to 241st in Daily Rankings with $476 Million Turnover - AInvest
Quest Diagnostics Well Positioned to Benefit From Strong Medical Utilization - Morningstar
Quest Diagnostics Q2 EarningsQuest Diagnostics (NYSE:DGX) - Benzinga
Quest Diagnostics Reports Strong Q2 Earnings, Exceeds ExpectationsNews and Statistics - IndexBox
Quest Diagnostics: Q2 Earnings Snapshot - Chron
Quest Diagnostics rises on upbeat results, guidance raise (DGX:NYSE) - Seeking Alpha
Quest Diagnostics raises annual forecasts on strong diagnostic testing demand - whbl.com
Quest Diagnostics Beats Q2 Earnings & Revenue Estimates, Stock Rises - The Globe and Mail
Quest Diagnostics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
What to Expect From Quest Diagnostics' Q2 2025 Earnings Report - MSN
Quest Diagnostics (DGX) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Quest Diagnostics Inc (DGX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):